Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Atara Biotherapeutics Inc shares valued at $15,000 were sold by Grant-Huerta Yanina on May 16 ’25. At $6.76 per share, Grant-Huerta Yanina sold 2,218 shares. The insider’s holdings dropped to 37,067 shares worth approximately $0.3 million following the completion of this transaction.
Also, Nguyen AnhCo sold 3,276 shares, netting a total of over 22,156 in proceeds. Following the sale of shares at $6.76 each, the insider now holds 70,847 shares.
Before that, Nguyen AnhCo had added 3,471 shares to its account. In a trade valued at $26,414, the Director bought Atara Biotherapeutics Inc shares for $7.61 each.
As published in a research note from Mizuho on November 09, 2023, Atara Biotherapeutics Inc [ATRA] has been rated down from a Buy to a Neutral and the price target has been revised to $1 from $31. Analysts at H.C. Wainwright downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early November. As of November 09, 2023, Evercore ISI has decreased its “an Outperform” rating to a “an In-line” for ATRA. Earlier on July 20, 2022, Citigroup downgraded its rating. Their new recommendation was “a Sell” for ATRA stock which previously was a “a Neutral”.
Analyzing ATRA Stock Performance
On last trading session,, Atara Biotherapeutics Inc [NASDAQ: ATRA] rose 2.82% to $8.02. The stock’s lowest price that day was $7.8382, but it reached a high of $8.28 in the same session. During the last five days, there has been a drop of approximately -9.99%. Over the course of the year, Atara Biotherapeutics Inc shares have dropped approximately -39.74%. Shares of the company reached a 52-week high of $18.70 on 01/06/25 and a 52-week low of $5.01 on 04/07/25.
Support And Resistance Levels for Atara Biotherapeutics Inc (ATRA)
According to the 24-hour chart, there is a support level at 7.78, which, if violated, would cause prices to drop to 7.54. In the upper region, resistance lies at 8.27. The next price resistance is at 8.52. RSI (Relative Strength Index) is 49.85 on the 14-day chart, showing neutral technical sentiment.
Is Atara Biotherapeutics Inc subject to short interest?
Stocks of Atara Biotherapeutics Inc saw a sharp steep in short interest on 2025-05-30 dropping by -0.15 million shares to 0.37 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 0.52 million shares. A decline of -42.12% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.0 of the overall float, the days-to-cover ratio (short ratio) decline to 5.0.
Which companies own the most shares of Atara Biotherapeutics Inc (ATRA)?
In terms of Atara Biotherapeutics Inc share price expectations, FactSet research, analysts set an average price target of 10 in the next 12 months, up nearly 28.21% from the previous closing price of $7.80. Analysts anticipate Atara Biotherapeutics Inc stock to reach 18 by 2025, with the lowest price target being 3. In spite of this, 1 analysts ranked Atara Biotherapeutics Inc stock as Sell at the end of 2025. On July 13, 2022, Stifel assigned a price target of “a Hold” to the stock and downgraded coverage with a $5.
